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Q 
What would you say is the primary focus of 
your research effort (how do you refer to 
your ‘subarea’)?
A 
In Silico Oncology
Q 
What do you consider to be the most 
signiﬁ  cant open questions and research chal-
lenges in cancer informatics?
A 
I think that understanding and effectively 
modeling the dynamics of cancer and affected 
normal tissues at all biocomplexity levels by using 
any efﬁ  cient combination of mathematical and 
computer modeling approaches (discrete, con-
tinuous, deterministic, stochastic, analytical, 
numerical, algorithmic etc.) is the fundamental 
open question and research challenge in cancer 
informatics. Obviously this is a long term target 
which presupposes success in understanding and 
modeling every single critical mechanism involved 
in cancer and affected normal tissue development 
and treatment response, as well as the subsequent integration of all those modeling modules.
As the demands of such an endeavor are tremendous, I think that a parallelism with the history of 
Newtonian physics might serve as a source of guidance, inspiration and courage. It has been suggested 
that cancer epitomizes the entire biology. In this context I think that a title like: “Philosophiae Natura-
lis Principia Mathematica: Pars II, Materia Vivens” (Mathematical Principles of Natural Philosophy: 
Part II, Living Matter) might to some extent describe the collaborative efforts on a worldwide scale to 
apply the analytical way of thinking on the description of natural phenomena (mechanisms) involving 
living matter and especially on those related to cancer. Obviously stochasticity would be a key player 
in such an approach. A thorough, quantitative, clinically validated and exploitable understanding of 
such multi-scale phenomena is expected to dramatically accelerate the achievement of cancer cure on 
a patient individualized basis through treatment optimization in silico (on the computer). Such an 
expectation seems to be compatible with the US National Cancer Program’s goal of eliminating the 
suffering and death due to cancer by 2015.
Q 
What do you consider to be the most signiﬁ  cant developments as a result of research cancer infor-
matics?
A 
Radiotherapy treatment planning is perhaps the ﬁ  rst large scale achievement of cancer informatics. 
Recent achievements include the design of cancer drugs, the simulation and elucidation of speciﬁ  c 
tumor growth mechanisms, the modeling of molecular networks involved in cancer etc.
Q 
Tell us about your collaborative research. How much of your effort is typically focused on helping 
to provide cancer researchers with clinically signiﬁ  cant results?
A 
I would say that roughly 40% of my effort is focused on helping providing cancer researchers with 
clinically signiﬁ  cant results. Within this frame a careful use of clinical data stemming from clinical 
trials as well as directly form collaborating hospitals (imaging, histopathological, molecular, historical 
data) is being made in order to validate, adapt and optimize the simulation models that my group has 
been developing.84
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Q 
What do you consider to be the most pressing 
challenges or barriers to success in cancer 
research?
A 
I consider lack of efﬁ  cient coordination of the 
experimental, theoretical and computational 
research work on a worldwide scale is one of the 
most pressing barriers to cancer research. Hopefully 
recent efforts based on grid and other forms of 
information technology seem to considerably alle-
viate this problem, but it won’t be enough. IT is 
important; however, equal funding and effort 
should be put into the development of sufﬁ  ciently 
fine-grained analytical informatics, supporting 
research on algorithms for cancer modeling, includ-
ing computationally intensive statistical analyses, 
understanding information ﬂ  ow about cancer and 
cancer care as multi-scale phenomena. Past funding 
priorities in basic research, and now in informatics, 
have actually starved the development of new 
insight from mathematics, intensive computing, 
and statistics, and what we do with the integrated 
data is, in many ways, fundamentally much more 
important that how we store and transfer it. The 
theory in these models must be made to reﬂ  ect the 
complexity of cancer, and cancer research and 
clinical practice must be made ready to be informed 
by these models. This is especially challenging 
because we must avoid building IT systems that 
limit discovery and exploration by hard-wiring a 
particular knowledge based or paradigm. Ideally, 
the IT infrastructure would be built with a deep 
understanding of the intrinsic complexity and multi-
scale nature of the biological processes involved in 
cancer occurrence and progression. In other words 
apart from a sophisticated infrastructure con-
structor, informatics is called to act - to a certain 
extent-as the “successor” of classical mathemat-
ics i.e. as the descriptive language of hyper-
complex natural phenomena such as cancer. 
Resolving this paradox requires discourse among 
open minds, and Cancer Informatics is an important 
start in facilitating such discussions.
Q 
What do you consider to be the most signiﬁ  -
cant developments as a result of cancer 
research?
A 
I think that increase in the rate of curability 
and life expectancy as well as improvement of 
the quality of life for speciﬁ  c cancers are the most 
signiﬁ  cant end results of cancer research. Interme-
diate results include, for example, development of 
highly sophisticated technology for radiotherapy 
treatment planning, computer based design of 
cancer drugs, modeling and simulation of molecu-
lar pathways, tumor growth and response to thera-
peutic interventions etc.
Q 
When did you decide to be, or realize that you 
were, involved primarily in informatics as a 
research focus?
A 
I decided to get involved primarily in informat-
ics as a research focus just before the prepara-
tion of my diploma thesis at the Department of 
Electrical and Computer Engineering, National 
Technical University of Athens.
Q 
Do you currently conduct research on diseases 
other than cancer?
A 
No.
Q 
Tell us about three or four ‘must-have’ essential 
informatics computing or research resources 
that you use on a regular basis developed by some-
one other than yourself or collaborators. Why are 
these resources so useful, and why do you consider 
them essential?
A 
Visual C++ ™, Matlab ™, AVS ™, CAVE™ 
Immersive Virtual Reality System
Q 
What do you think about the development of 
open access publishing and open access devel-
opment? How has either changed your perspective 
on research and development practices?
A 
I think that open access publishing and open 
access development have become sine qua non 
necessities in modern collaborative scientific 
research. Two large scale international research 
projects in which I participate, namely the US NIH 
Cancer Integrative Biology Program (Center for 
the Development of a Virtual Tumor) and the 
recently funded European IST project Advancing 
Clinicogenomic Trials on Cancer (ACGT) have 
adopted the open access development strategy.
Q 
What books do you think should be required 
of researchers involved in informatics? In 
cancer research?
A 
I think that researchers involved in both cancer 
research and informatics need updated books 
on 1) general biology including biochemistry 2) 
pharmacology 3) radiobiology 4) cancer pathology, 
biology and treatment 5) algorithms and complexity 85
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focused on cancer modeling and related issues 6) 
mathematical analysis (differential equations etc.) 
7) statistics 8) general informatics (e.g. computer 
languages, data bases, image processing, virtual 
reality, algorithm optimization, grid technologies 
etc.) 9) other related subjects.
Q
What books are on your current reading list?
A 
A quite large number of books covering all the 
previously mentioned areas are on my current 
reading list. Especially, I would like to mention 
the review book Cancer Bioinformatics: from 
therapy design to treatment Edited by Sylvia 
Nagl © 2006 John Wiley & Sons, Ltd (http://eu.
wiley.com/WileyCDA/WileyTitle/product 
Cd-0470863048,descCd-tableOfContents.html)
A chapter entitled Computer Simulation of Tumour 
Response to Therapy (by G. S. Stamatakos and 
N. Uzunoglu) which appears within this book gives 
a comprehensive outline of some representative 
efforts concerning both the shaping and the 
development of the emerging ﬁ  eld of In Silico 
Oncology.
Q 
Do you teach any courses? If so which ones?
A 
Yes. Within the last years I have taught selected 
chapters and laboratory classes on Simulation 
of Physiological Systems as well as full courses 
on Electromagnetic Fields and Applications.
Q 
List the historical research ﬁ  gures that you think 
have most inﬂ  uenced how you think about 
research? Why are these inﬂ  uences signiﬁ  cant?
A 
I think that the historical ﬁ  gures that have most 
inﬂ  uenced my way of thinking about research 
are the following: 1) Aristotle, the founder of the 
science ofbiology, through his extensive zoological 
descriptions and his detailed and mostly objective 
observations on the biological phenomena 2) Isaac 
Newton, the founder of classical physics, through 
his parsimonious (laconic) mathematical descrip-
tion of the basic natural phenomena 3) Gregor 
Johann Mendel, the founder of genetics, through 
his insistent experimentation and the ingenious 
phenomenological interpretation of his experimen-
tal data; still more, through his determination to 
carry on research despite the unusually unfavorable 
circumstances he faced during his life.
Q 
Which research meetings do you attend on a 
regular basis (please provide URLs)?
A
■   IEEE EMBS (http://www.ee.cuhk.edu.hk/ 
EMBC05shanghai/),
■   Drug  Discovery  Technology(http://www.drugdisc.
com/section.asp),
■   ECO (http://professional.cancerconsultants.
com/conference_ecco_2003.aspx),
■ ASTRO (http://www.astro.org/),
■   ESTRO  (http://www.estroweb.org/estro/index.
cfm)
Q 
Please tell us about your own resource devel-
opment efforts (limit 3). Which of your com-
puting resources or research papers would you like 
most people to know about?
A 
1) Development of software simulating tumor 
growth and response to radiotherapeutic 
schemes 2) Development of software simulating 
tumor growth and response to chemotherapeutic 
schemes 3) Development of software simulating 
the response of normal tissues to radiation therapy 
(and prospectively chemotherapy).
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Q 
If you could change three things about how 
informatics research is conducted, used, per-
ceived, or resourced, what would they be?
A 
I would promote 1) deeper understanding of the 
problems to be addressed before informatics 
tools are applied or developed 2) emphasis on the 
application driven informatics development 
3) tighter collaboration between all participants 
involved in informatics research and development.
Q 
What do you think are the most signiﬁ  cant can-
cer research studies in the last year that have 
been made possible by advances in informatics?
A 
Clinical applications of DNA and other 
molecular irrays, simulation of the dynamics 
of molecular networks, progress in the modeling 
of tumor growth and response to therapeutic inter-
ventions.
Q 
Do you have any further thoughts that you 
might like to share?
A 
I think that a new era in cancer research is 
dawning. Cancer Informatics is undoubtedly 
a key player. New challenges include the develop-
ment of highly specialized algorithms for the 
simulation of dynamic phenomena at all levels of 
biocomplexity, hyper-high performance hardware, 
promotion of the open access policy etc. Further-
more, the immense necessities of cancer research 
are expected to greatly contribute to the progress 
of informatics itself. By analogy with the unparal-
leled progress achieved in mathematical analysis 
as a result of the needs of classical physics it would 
be quite reasonable to predict a tremendous impact 
on the development of informatics by the needs of 
biology and cancer science, especially if funding 
priorities are aligned to promote such a synthesis.
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